Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) closed the day trading at $397.55 down -3.65% from the previous closing price of $412.63. In other words, the price has decreased by -$3.65 from its previous closing price. On the day, 1.61 million shares were traded. ALNY stock price reached its highest trading level at $410.04 during the session, while it also had its lowest trading level at $387.03.
Ratios:
For a better understanding of ALNY, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 19.28 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 237.27. For the most recent quarter (mrq), Quick Ratio is recorded 2.49 and its Current Ratio is at 2.54. In the meantime, Its Debt-to-Equity ratio is 11.86 whereas as Long-Term Debt/Eq ratio is at 11.17.
On August 04, 2025, Oppenheimer Upgraded its rating to Outperform which previously was Perform but kept the price unchanged to $490.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 17 ’25 when Fitzgerald Kevin Joseph sold 12,128 shares for $452.18 per share. The transaction valued at 5,483,990 led to the insider holds 21,264 shares of the business.
Fitzgerald Kevin Joseph bought 12,128 shares of ALNY for $5,445,472 on Nov 17 ’25. On Nov 12 ’25, another insider, Greenstreet Yvonne, who serves as the Chief Executive Officer of the company, sold 15,650 shares for $453.69 each. As a result, the insider received 7,100,322 and left with 65,409 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALNY now has a Market Capitalization of 52521844736 and an Enterprise Value of 52570533888. As of this moment, Alnylam’s Price-to-Earnings (P/E) ratio for their current fiscal year is 1653.70, and their Forward P/E ratio for the next fiscal year is 52.82. For the stock, the TTM Price-to-Sale (P/S) ratio is 16.36 while its Price-to-Book (P/B) ratio in mrq is 224.01. Its current Enterprise Value per Revenue stands at 16.377 whereas that against EBITDA is 163.76.
Stock Price History:
The Beta on a monthly basis for ALNY is 0.31, which has changed by 0.6911758 over the last 52 weeks, in comparison to a change of 0.13613915 over the same period for the S&P500. Over the past 52 weeks, ALNY has reached a high of $495.55, while it has fallen to a 52-week low of $205.87. The 50-Day Moving Average of the stock is -12.16%, while the 200-Day Moving Average is calculated to be 9.85%.
Shares Statistics:
Over the past 3-months, ALNY traded about 1.09M shares per day on average, while over the past 10 days, ALNY traded about 1203860 shares per day. A total of 131.79M shares are outstanding, with a floating share count of 129.79M. Insiders hold about 1.77% of the company’s shares, while institutions hold 99.36% stake in the company. Shares short for ALNY as of 1764288000 were 3960190 with a Short Ratio of 3.65, compared to 1761868800 on 3769098. Therefore, it implies a Short% of Shares Outstanding of 3960190 and a Short% of Float of 3.94.
Earnings Estimates
At present, 11.0 analysts are actively evaluating the performance of Alnylam Pharmaceuticals Inc (ALNY) in the stock market.The consensus estimate for the next quarter is $2.09, with high estimates of $2.55 and low estimates of $1.55.
Analysts are recommending an EPS of between $5.99 and $3.76 for the fiscal current year, implying an average EPS of $4.96. EPS for the following year is $10.61, with 12.0 analysts recommending between $13.86 and $6.44.
Revenue Estimates
20 analysts predict $1.17B in revenue for. The current quarter. It ranges from a high estimate of $1.61B to a low estimate of $1.04B. As of. The current estimate, Alnylam Pharmaceuticals Inc’s year-ago sales were $593.17MFor the next quarter, 20 analysts are estimating revenue of $1.22B. There is a high estimate of $1.31B for the next quarter, whereas the lowest estimate is $1.11B.
A total of 25 analysts have provided revenue estimates for ALNY’s current fiscal year. The highest revenue estimate was $4.23B, while the lowest revenue estimate was $3.42B, resulting in an average revenue estimate of $3.74B. In the same quarter a year ago, actual revenue was $2.25BBased on 24 analysts’ estimates, the company’s revenue will be $5.36B in the next fiscal year. The high estimate is $6.12B and the low estimate is $4.34B.
